Fulcrum Therapeutics (US.FULC)
Capital Allocation Audit · Period: 2017 – 2026
Key Metrics
US.FULC · YoY: 2026 H1 vs 2025 H1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.3% | → |
| ROE | -14.5% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.02 | ↑ |
| Gross Margin | - | → |
US.FULC (Fulcrum Therapeutics) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 100.3% → ROE -14.5% ↑ Cash Conversion - → D/E Ratio 0.02 ↑ Gross Margin - →
Key Metrics
US.FULC (Fulcrum Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 100.3% →ROE -14.5% ↑Cash Conversion - →D/E Ratio 0.02 ↑Gross Margin - →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies